4//SEC Filing
Aeglea BioTherapeutics, Inc. 4
Accession 0001140361-16-060929
$SYRECIK 0001636282operating
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 5:07 PM ET
Size
10.3 KB
Accession
0001140361-16-060929
Insider Transaction Report
Form 4
Lowe David George
DirectorCEO and President
Transactions
- Conversion
Series A Preferred Stock
2016-04-12−2,857→ 0 total(indirect: By Trust)Exercise: $0.00→ Common Stock (2,857 underlying) - Conversion
Series B Preferred Stock
2016-04-12−2,801→ 0 total(indirect: By Trust)Exercise: $0.00→ Common Stock (2,801 underlying) - Conversion
Common Stock
2016-04-12+5,658→ 5,658 total(indirect: By Trust)
Holdings
- 206,382
Common Stock
Footnotes (2)
- [F1]In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.
- [F2]The Reporting Person serves as a co-trustee.
Documents
Issuer
Aeglea BioTherapeutics, Inc.
CIK 0001636282
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001636282
Filing Metadata
- Form type
- 4
- Filed
- Apr 11, 8:00 PM ET
- Accepted
- Apr 12, 5:07 PM ET
- Size
- 10.3 KB